|
Synonyms: burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023
burosumab is an approved drug (EMA & FDA (2018))
Compound class:
Antibody
Comment: Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity [1,4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [11]. |
| Bioactivity Comments |
| Patent US7883705 provides preclinical in vitro and in vivo results regarding the function of burosumab (C10) in relation to FGF23 regulation of blood phosphate levels, but does not specify an affinity value for the antibody-FGF23 binding interaction [11]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
